- Conditions
- Cystic Fibrosis Lung
- Interventions
- 4D-710
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- IMO-8400
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Advanced Solid Tumors
- Interventions
- SP-2577 Seclidemstat
- Drug
- Lead sponsor
- Salarius Pharmaceuticals, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Santa Monica, California
- Conditions
- Cancer
- Interventions
- Consult visit
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
- Interventions
- DS-1594b, Azacitidine, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin, Mesna, Methotrexate, Prednisone, Rituximab, Venetoclax, Vincristine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors, Hematologic Malignancies
- Interventions
- INCA036873
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more
- Conditions
- Safety in Asthma Patients
- Interventions
- ASY202, Placebo
- Combination Product
- Lead sponsor
- Aspeya, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Glendale, Arizona • Anaheim, California • Tulsa, Oklahoma + 2 more
- Conditions
- BH4 Deficiency, Hyperphenylalaninemia
- Interventions
- PTC923
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • Dallas, Texas • Salt Lake City, Utah + 1 more
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- RX108
- Drug
- Lead sponsor
- NeuPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer
- Interventions
- 68Ga-R11228, 177Lu-R11228
- Drug
- Lead sponsor
- Radionetics Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Glen Burnie, Maryland • Princeton, New Jersey + 3 more
- Conditions
- Malaria
- Interventions
- BNT165c, BNT165d, Placebo
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
- Conditions
- Advanced Solid Tumor
- Interventions
- PM54, Irinotecan, Doxorubicin
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • Houston, Texas
- Conditions
- Burn Any Degree Involving 20-29 Percent of Body Surface, Burn Any Degree Involving 30-39 Percent of Body Surface, Burn Any Degree Involving 40-49 Percent of Body Surface, Burn Any Degree Involving 50-59 Percent of Body Surface, Burn Any Degree Involving 60-65 Percent of Body Surface, Fluid Resuscitation
- Interventions
- CeraLyte 90
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- ABI-009, Gemcitabine
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- EGFR Mutant Advanced Non-small Cell Lung Cancer
- Interventions
- JIN-A02
- Drug
- Lead sponsor
- J Ints Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Health Volunteers
- Interventions
- CTP-543, Fluconazole
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV Infections
- Interventions
- PGDM1400LS (5mg/kg, IV), PGDM1400LS (20mg/kg, IV), PGDM1400LS (20mg/kg, SC), PGDM1400LS (40mg/kg, IV), PGDM1400LS (40mg/kg, SC), PGDM1400LS (1.4g, IV), PGDM1400LS (1.4g, SC), VRC07-523LS (20mg/kg, IV), VRC07-523LS (20mg/kg, SC), VRC07-523LS (1.4g, IV), VRC07-523LS (1.4g, SC), VRC07-523LS (40mg/kg, IV), PGT121.414.LS (20mg/kg, IV), PGT121.414.LS (20mg/kg, SC), PGT121.414.LS (1.4g, IV), PGT121.414.LS (1.4g, SC), PGT121.414.LS (40mg/kg, IV)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Interventions
- Olaparib, Tremelimumab
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Albuquerque, New Mexico • Columbus, Ohio + 1 more
- Conditions
- Non-Hodgkin's Lymphoma,, Solid Tumors
- Interventions
- PPI-2458
- Drug
- Lead sponsor
- PRAECIS Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Albuquerque, New Mexico + 3 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ondansetron, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
- Interventions
- XMT-2056
- Drug
- Lead sponsor
- Day One Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Stanford, California • Celebration, Florida + 8 more
- Conditions
- Epilepsy Intractable
- Interventions
- ABI-009
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 3 Years to 26 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
- Interventions
- HER2-specific chimeric antigen receptor (CAR) T cell
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2039
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy
- Interventions
- PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Miami, Florida